EL.EN.
Thanks to the El.En. Group of Calenzano, Florence, a multinational specialized in laser production for medical and industrial applications, and for conservation of artistic heritage, an event was organized to celebrate the just over 40 years since it was founded in the presence of the 2018 Nobel Prize winner for Physics, Gérard Mourou, and other prominent professors of international acclaim who contributed to pioneering research in the field of laser physics, paving the way for a multitude of scientific and medical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005326/en/
G.Mourou, O.Svelto and P.Salvadeo special guest stars at El.En. exclusive event (Photo: Business Wire)
The event was also held to honor two shining stars in the world of physics: The Nobel prize winner Gérard Mourou, who, thanks to the General Manager of El.En., Mr. Paolo Salvadeo, was given the prestigious honor of receiving the Key to the City of Florence from the Mayor of Florence in a separate public ceremony in the afternoon, and Orazio Svelto, Professor Emeritus of Polytechnic of Milan, father of laser in Italy. Prof. Svelto invented the so-called “hollow fiber compressor” making it possible to achieve laser impulses lasting attoseconds, with previously unimaginable peak power. This system is currently used in many laboratories the world over conducting cutting edge scientific research and non-linear spectroscopy.
During the gala dinner in the Salone dei Cinquecento of Palazzo Vecchio, in the presence of the major political authorities, the director of the Uffizi Gallery, of Console USA, and other institutional personalities and of the world of laser, Prof. Mourou shared his vision of the future of science, starting with the studies that earned him his Nobel prize for inventing the so-called Chirped Pulse Amplification (CPA), developed in collaboration with Donna Theo Strickland. It is a technique that, thanks to the generation of ultra-brief and high intensity impulses, has made laser even more versatile and enabled exploration of previously unknown dynamics of physics. A notable presence at the gala dinner was Prof. Sune Svamberg, who for many years was on the Nobel Committee for Physics, two years during which he was president, and Prof. Ursula Keller, one of the most acclaimed and well-known scientists in the world in the field of optoelectronics and photonics.
“It’s an honor and I take great pride in being able to create and maintain a deep connection between the world of academics and industry. This shows how crucial collaboration is between these worlds to conduct studies and make discoveries that improve the people’s quality of life. An osmosis of knowledge and a continuous and stimulating dialog that mark continuity among professors and alumni, many of whom dedicate their daily lives in the company laboratories of our group,” affirmed Paolo Salvadeo, General Manager of the El.En. Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005326/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
